nct_id,title,phase,status,study_type,conditions,interventions,molecular_targets,sponsor,collaborators,enrollment_count,start_date,completion_date,locations,needs_review,source_url
NCT01441089,Collection of Blood From Therapeutic Trial Participants for Analysis of Genetic Differences in Drug Disposition and Pharmacokinetics of Probe Medications,,Recruiting,Observational,Prostate Cancer; Breast Cancer; Lung Cancer; Ovarian Cancer; Lymphoma,,,National Cancer Institute (NCI),,1100,2012-05-21,,United States,No,https://clinicaltrials.gov/study/NCT01441089
NCT01913106,Phase I-II Study HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer With or Without Metastatic Disease,Phase 1/Phase 2,Recruiting,Interventional,Prostatic Neoplasms,HSV-tk +Valacyclovir in Combination with Brachytherapy,,The Methodist Hospital Research Institute,,25,2007-06-05,2028-12-05,United States,No,https://clinicaltrials.gov/study/NCT01913106
NCT02000089,The Cancer of the Pancreas Screening-5 CAPS5)Study,Phase 3,Recruiting,Interventional,Pancreas Cancer; Peutz-Jeghers Syndrome (PJS); Gene Mutation; Germline Mutation Carrier; Lynch Syndrome,Secretin; MRI; Tumor marker gene test with CA19-9,,Johns Hopkins University,National Cancer Institute (NCI); National Institutes of Health (NIH); American Association for Cancer Research,9000,2014-01-06,2029-06-05,United States,No,https://clinicaltrials.gov/study/NCT02000089
NCT02302742,"PROspective Evaluation of GErmline Mutations, Cancer Outcome and Tissue Biomarkers: A Registry for Patients With Triple Negative Breast Cancer and Germline Mutations",,Recruiting,Observational,Breast Cancer; Hereditary Breast and Ovarian Cancer,,,University of Kansas Medical Center,,1500,2011-03-22,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT02302742
NCT02333604,Cancer Experience Registry: An Online Survey Research Study to Understand the Experiences of Cancer Patients and Caregivers,,Recruiting,Observational,Neoplasms; Cancer; Caregiver,,,"Cancer Support Community, Research and Training Institute, Philadelphia",,15000,2013-03-05,2035-12-05,United States,No,https://clinicaltrials.gov/study/NCT02333604
NCT02775461,Pancreas Disease and High Risk Registry,,Recruiting,Observational,Pancreas Cancer; Pancreatitis; Chronic Pancreatitis; Pancreatic Cyst; Family History of Pancreas Cancer; Genetic Mutations,,,Icahn School of Medicine at Mount Sinai,,1116,2013-03-01,2033-11-05,United States,No,https://clinicaltrials.gov/study/NCT02775461
NCT02861573,Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365),Phase 1/Phase 2,Recruiting,Interventional,Metastatic Castration-Resistant Prostate Cancer,Pembrolizumab 200 mg; Olaparib 400 mg; Docetaxel 75 mg/m^2; Prednisone 5 mg; Enzalutamide 160 mg; Dexamethasone 8 mg; Olaparib 300 mg; Abiraterone acetate 1000 mg; Lenvatinib; Pembrolizumab/Vibostolimab coformulation; Carboplatin; Etoposide; Belzutifan 120mg,,Merck Sharp & Dohme LLC,,1200,2016-11-17,2027-10-22,Australia; Canada; Denmark; France; Ireland; Italy; Mexico; Netherlands; New Zealand; Poland; Spain; Sweden; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT02861573
NCT03474913,Feasibility and Efficacy of Upright MP - MRI for Prostate Cancer Screening,,Recruiting,Observational,Prostate Cancer; Elevated PSA; Elevated Prostate Specific Antigen,Upright MRI; Standard MRI,,Icahn School of Medicine at Mount Sinai,The Fonar Corporation,550,2018-10-01,2026-07-01,United States,No,https://clinicaltrials.gov/study/NCT03474913
NCT03492424,Ablative Therapy in the Management of Prostate Cancer,,Recruiting,Observational,Prostate Cancer,cryotherapy,,Weill Medical College of Cornell University,Prostate Cancer Foundation,200,2018-01-02,2039-09-02,United States,No,https://clinicaltrials.gov/study/NCT03492424
NCT03568630,A Longitudinal Cohort Study to Identify Clinical and Blood Markers of Early Pancreas Cancer,,Recruiting,Observational,"Diabetes Mellitus, Type 2; PreDiabetes; Pancreas Cyst; Chronic Pancreatitis; Genetic Predisposition to Disease; Inherited Disease",,,University of Nebraska,National Cancer Institute (NCI); Virginia Mason Hospital/Medical Center; VA Nebraska Western Iowa Health Care System,1250,2018-07-26,2028-07-05,United States,No,https://clinicaltrials.gov/study/NCT03568630
NCT03574571,Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC),Phase 3,Recruiting,Interventional,Prostate Cancer,Docetaxel 75 mg/m2; Docetaxel 60 mg/m2; Radium-223,,Memorial Sloan Kettering Cancer Center,Bayer,738,2018-06-19,2027-04-01,Brazil; Netherlands; Spain; United States,No,https://clinicaltrials.gov/study/NCT03574571
NCT03620786,High-Intensity Focused Ultrasound for Focal Ablation of Prostate Tissue: An Observational Study of Multiparametric MRI and Ultrasound Fusion Imaging for Guidance,,Recruiting,Observational,Prostate Cancer,Sonablate HIFU device,,"University of California, Los Angeles",,100,2018-09-26,2028-01-31,United States,No,https://clinicaltrials.gov/study/NCT03620786
NCT03802851,HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer,Not Applicable,Recruiting,Interventional,Prostate Cancer; Lower Urinary Tract Symptoms,Holmium Laser Enucleation of Prostate (HoLEP),,University of Kansas Medical Center,,30,2019-09-19,2035-01-05,United States,No,https://clinicaltrials.gov/study/NCT03802851
NCT03972657,A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression,Phase 1/Phase 2,Recruiting,Interventional,Metastatic Castration-Resistant Prostate Cancer (mCRPC); Clear Cell Renal Cell Carcinoma (ccRCC),REGN5678; Cemiplimab,,Regeneron Pharmaceuticals,,345,2019-08-12,2027-11-15,United States,No,https://clinicaltrials.gov/study/NCT03972657
NCT04038502,"An Open-label, Multicenter Phase II Study to Compare the Efficacy of Carboplatin as First-line Followed by Second-line Olaparib Versus Olaparib as First-line Followed by Second-line Carboplatin in the Treatment of Patients With Castration Resistant Prostate Cancer Containing Homologous Recombination Deficiency",Phase 2,Recruiting,Interventional,"Metastatic Castrate Resistant Prostate Cancer; BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2; RAD51B, RAD51C, RAD51D, or RAD54L Mutations",Carboplatin; Olaparib,,VA Office of Research and Development,,100,2019-10-01,2027-08-31,United States,No,https://clinicaltrials.gov/study/NCT04038502
NCT04071236,"A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, &Amp; Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)",Phase 1/Phase 2,Recruiting,Interventional,Metastatic Castration-Resistant Prostate Carcinoma; Metastatic Malignant Neoplasm in the Bone; Metastatic Malignant Neoplasm in the Lymph Nodes; Stage IVB Prostate Cancer AJCC v8,Avelumab; Biospecimen Collection; Bone Scan; Computed Tomography; Magnetic Resonance Imaging; Peposertib; Questionnaire Administration; Radium Ra 223 Dichloride,,National Cancer Institute (NCI),,90,2020-10-14,2026-04-30,United States,No,https://clinicaltrials.gov/study/NCT04071236
NCT04090567,Overcoming PARP Inhibitor Resistance in BRCA Germline Mutation Positive Advanced Breast Cancer,Phase 2,Recruiting,Interventional,Advanced Breast Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Germline BRCA1 Gene Mutation; Germline BRCA2 Gene Mutation; HER2/Neu Negative; Metastatic Breast Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8,Cediranib; Ceralasertib; Olaparib,,M.D. Anderson Cancer Center,National Cancer Institute (NCI),60,2020-07-28,2027-12-31,United States,No,https://clinicaltrials.gov/study/NCT04090567
NCT04104893,A Phase 2 Study of a Checkpoint Inhibitor in Men With Progressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation,Phase 2,Recruiting,Interventional,Metastatic Castration Resistant Prostate Cancer,Pembrolizumab,,VA Office of Research and Development,Merck Sharp & Dohme LLC,40,2020-02-20,2025-12-31,United States,No,https://clinicaltrials.gov/study/NCT04104893
NCT04221542,"A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer",Phase 1,Recruiting,Interventional,Prostate Cancer,AMG 509; Abiraterone; Enzalutamide,,Amgen,BeiGene; BeOne (China only),479,2020-03-04,2032-03-21,Australia; China; Germany; Japan; Portugal; South Korea; Spain; Switzerland; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT04221542
NCT04254133,Genetic Information to Inform Treatment and Screening (GIFTS) Study for Prostate Cancer,,Enrolling by invitation,Observational,Prostate Carcinoma,Questionnaire; Biospecimen Collection; Genetic Testing; Genetic Counseling; Laboratory Biomarker Analysis,,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),1360,2018-11-30,2028-08-31,United States,No,https://clinicaltrials.gov/study/NCT04254133
NCT04315324,A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL),Phase 1/Phase 2,Recruiting,Interventional,Recurrent T Acute Lymphoblastic Leukemia; Refractory T Acute Lymphoblastic Leukemia; Refractory T Lymphoblastic Lymphoma; T Lymphoblastic Lymphoma,AKR1C3-activated Prodrug AST-3424; Biopsy Procedure; Biospecimen Collection; Bone Marrow Aspiration; Computed Tomography,,SWOG Cancer Research Network,National Cancer Institute (NCI),67,2021-02-08,2028-08-01,United States,No,https://clinicaltrials.gov/study/NCT04315324
NCT04337580,A Phase II Trial of FASN Inhibition by Omeprazole in Combination With Cabazitaxel in Patients With Docetaxel- and Castration-Resistant Prostate Cancer,Phase 2,Recruiting,Interventional,Prostate Cancer; Refractory Cancer; Castration Resistant Prostatic Cancer,Omeprazole 80 mg twice daily,,Wake Forest University Health Sciences,National Cancer Institute (NCI),50,2021-03-05,2028-04-05,United States,No,https://clinicaltrials.gov/study/NCT04337580
NCT04373564,Prospective Evaluation of Potential Effects of Repeated Gadolinium-based Contrast Agent (GBCA) Administrations of the Same GBCA on Motor and Cognitive Functions in Neurologically Normal Adults in Comparison to a Non-GBCA Exposed Control Group,Phase 4,Recruiting,Interventional,Motor Function; Cognitive Function; Contrast Media,Motor Tests; Cognitive Tests; Unenhanced-MRI of the brain; Gadolinium Measurements; Gadoxetate disodium; Gadobenate dimeglumine; Gadodiamide; Gadoterate meglumine; Gadobutrol; Gadoteridol,,Guerbet,Bayer AG (Sponsor); Bracco (Sponsor); GEHC (Sponsor),2076,2021-03-24,2028-12-31,Brazil; Canada; France; Germany; Italy; Russia; South Korea; United States,No,https://clinicaltrials.gov/study/NCT04373564
NCT04662580,"A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer",Phase 1,Recruiting,Interventional,Metastatic Prostate Cancer,ARX517; Apalutamide; Abiraterone acetate; Prednisone,,"Janssen Research & Development, LLC",,183,2024-12-09,2028-12-29,United States,No,https://clinicaltrials.gov/study/NCT04662580
NCT04706663,A Multi-Center Natural History Study of Precision-Based Genomics in Prostate Cancer,,Recruiting,Observational,Prostate Cancer,,,National Cancer Institute (NCI),,2000,2021-09-14,2027-06-30,United States,No,https://clinicaltrials.gov/study/NCT04706663
NCT04729114,"Phase 1, Open-Label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer",Phase 1,Recruiting,Interventional,Prostate Cancer; Metastatic Castration Resistant Prostate Cancer; Metastatic Castration-sensitive Prostate Cancer,PRL-02 injection; prednisone; dexamethasone; enzalutamide,,"Astellas Pharma Global Development, Inc.",,174,2021-06-14,2029-05-31,Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT04729114
NCT04808427,Magnetic Resonance Image (MRI) Guided High Energy Ultrasound for Focal Prostate Cancer Ablation,Not Applicable,Recruiting,Interventional,Prostate Cancer,TULSA-PRO,,National Cancer Institute (NCI),,21,2023-11-20,2027-09-01,United States,No,https://clinicaltrials.gov/study/NCT04808427
NCT04858334,"APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation",Phase 2,Recruiting,Interventional,Pancreatic Acinar Cell Carcinoma; Pancreatic Adenosquamous Carcinoma; Pancreatic Squamous Cell Carcinoma; Resectable Pancreatic Acinar Cell Carcinoma; Resectable Pancreatic Adenocarcinoma; Resectable Pancreatic Adenosquamous Carcinoma; Resectable Pancreatic Carcinoma,Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Olaparib; Placebo Administration,,National Cancer Institute (NCI),,152,2021-06-22,2027-10-31,Israel; Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT04858334
NCT04890613,Phase Ib Expansion Study of CX-5461 in Patients With Solid Tumours and BRCA2 and/or PALB2 Mutation,Phase 1,Recruiting,Interventional,Advanced Solid Tumor,CX-5461,,"Senhwa Biosciences, Inc.",,52,2021-09-08,2026-12-05,Canada; United States,No,https://clinicaltrials.gov/study/NCT04890613
NCT04898634,"A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer",Phase 1,Recruiting,Interventional,Prostatic Neoplasms,JNJ-78278343,,"Janssen Research & Development, LLC",,216,2021-07-13,2027-02-10,China; France; Japan; Netherlands; Spain; United States,No,https://clinicaltrials.gov/study/NCT04898634
NCT04970056,Pancreatic Cancer Early Detection Consortium,,Recruiting,Observational,Pancreas Cancer; Pancreas Cyst; Pancreatic Ductal Adenocarcinoma; Genetic Predisposition,,,Arbor Research Collaborative for Health,,10000,2020-09-18,2030-12-31,Australia; Canada; Hungary; Iceland; Israel; Italy; Singapore; Spain; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04970056
NCT04995198,PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness,,Recruiting,Observational,Prostate Cancer,,,Prostate Cancer Clinical Trials Consortium,"Memorial Sloan Kettering Cancer Center; Fred Hutchinson Cancer Center; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Advancing Cancer Treatment, Inc.",500,2021-05-03,2036-02-26,United States,No,https://clinicaltrials.gov/study/NCT04995198
NCT05125016,Phase 1/2 Study of REGN4336 (a PSMAxCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab or REGN5678 (a PSMAxCD28 Bispecific Antibody) in Patients With Metastatic Castration-Resistant Prostate Cancer,Phase 1/Phase 2,Recruiting,Interventional,Metastatic Castration-resistant Prostate Cancer,REGN4336; Cemiplimab; REGN5678; Sarilumab,,Regeneron Pharmaceuticals,,370,2021-11-30,2027-01-14,United States,No,https://clinicaltrials.gov/study/NCT05125016
NCT05129605,Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS),,Recruiting,Observational,Prostatic Neoplasm; Prostate Cancer; BRCA2 Mutation; BRCA1 Mutation; ATM Gene Mutation; MMR Mutation; Lynch Syndrome; Genetic Predisposition to Disease,Prostate cancer screening,,Massachusetts General Hospital,,400,2020-02-12,2040-12-05,United States,No,https://clinicaltrials.gov/study/NCT05129605
NCT05155046,Phase II Trial of 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy,Phase 2,Recruiting,Interventional,Localized Prostate Cancer,18F-DCFPyL,,National Cancer Institute (NCI),,130,2022-08-31,2029-12-31,United States,No,https://clinicaltrials.gov/study/NCT05155046
NCT05168618,AtezoCab: A Phase II Study of Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Non-Measurable Disease,Phase 2,Recruiting,Interventional,Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8,Atezolizumab; Cabozantinib S-malate,,University of Utah,National Cancer Institute (NCI),33,2022-03-11,2027-01-05,United States,No,https://clinicaltrials.gov/study/NCT05168618
NCT05411354,Analyzing Clinical Trial Experiences of Prostate Cancer Patients To Determine How Trial Attributes Affect Completion Rates For Specific Demographic Groups,,Not yet recruiting,Observational,Prostate Cancer,,,Power Life Sciences Inc.,,400,2024-09-05,2026-09-05,United States,No,https://clinicaltrials.gov/study/NCT05411354
NCT05422911,"A Phase 2 Randomized Study of YONSA® (Abiraterone Acetate), Enzalutamide or Apalutamide as First Line Therapy in Veterans With Castrate-sensitive Prostate Cancer",Phase 2,Not yet recruiting,Interventional,"Metastatic Cancer; Neoplasm, Prostate",Abiraterone acetate; Apalutamide; Enzalutamide,,James J. Peters Veterans Affairs Medical Center,,200,2022-06-30,2026-06-30,United States,No,https://clinicaltrials.gov/study/NCT05422911
NCT05434234,"A Phase 1A/1B, Multicenter, Nonrandomized, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL201 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumor,YL201; YL201; YL201 and atezolizumab,,"MediLink Therapeutics (Suzhou) Co., Ltd.",,312,2022-05-25,2027-10-06,Canada; China; France; Poland; Spain; United States,No,https://clinicaltrials.gov/study/NCT05434234
NCT05498272,A Phase 2 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations (NePtune),Phase 2,Recruiting,Interventional,Prostate Cancer; BRCA1 Mutation; BRCA2 Mutation; Prostatic Adenocarcinoma; High-Risk Cancer,Olaparib; LHRH agonist,,"Rana McKay, MD","AstraZeneca; University of California, San Diego",32,2023-02-01,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT05498272
NCT05515978,"A Randomized, Pragmatic, Adaptive Trial of Metformin for Glucose Intolerance or Increased Body Mass Index in Prostate Cancer Patients",Early Phase 1,Recruiting,Interventional,Prostate Cancer,Metformin; Lifestyle Modification,,"University of Colorado, Denver",,100,2022-10-10,2036-11-06,United States,No,https://clinicaltrials.gov/study/NCT05515978
NCT05519449,"A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer",Phase 1,Recruiting,Interventional,Prostate Cancer; Metastatic Castration-resistant Prostate Cancer; Castration Resistant Prostatic Cancer,JANX007; Darolutamide,,Janux Therapeutics,,272,2022-09-15,2028-12-05,Australia; United States,No,https://clinicaltrials.gov/study/NCT05519449
NCT05587439,Investigating Hereditary Risk In Thoracic Cancers (INHERIT),,Recruiting,Observational,Lung Cancer; Genetic Disease; Genetic Predisposition; Hereditary Diseases,Data and Specimen Collection,,Dana-Farber Cancer Institute,,500,2023-01-01,2027-11-01,United States,No,https://clinicaltrials.gov/study/NCT05587439
NCT05608694,MRI Screening in Men at High Risk of Developing Prostate Cancer,Not Applicable,Recruiting,Interventional,Prostate Cancer Screening,Prostate MRI,,University of Chicago,,250,2022-03-02,2039-03-01,United States,No,https://clinicaltrials.gov/study/NCT05608694
NCT05625529,Exoluminate Study: Observational Registry Study to Assess Exo-PDAC Assay Performance for Detection of Pancreatic Adenocarcinoma (PDAC) in High-Risk or Clinically Suspicious Patients,,Recruiting,Observational,Pancreas Cancer; Exosomes; Extracellular Vesicles; Pancreatic Neoplasms,,,Biological Dynamics,,1000,2022-12-19,2028-01-01,United States,No,https://clinicaltrials.gov/study/NCT05625529
NCT05647564,PET/CT Characterization of Treatment Resistance of AR-targeted Therapies in mCRPC,Not Applicable,Recruiting,Interventional,Prostate Cancer,F-fluorodeoxyglucose positron emission tomography (FDG PET); prostate-specific membrane antigen positron emission tomography (PSMA PET),,"University of Wisconsin, Madison",,20,2023-03-06,2026-03-01,United States,No,https://clinicaltrials.gov/study/NCT05647564
NCT05694715,Combination Therapy of Niraparib and Irinotecan in Cancers With Mutations in DNA Repair Genes,Phase 1,Recruiting,Interventional,Metastatic Solid Tumor; BRCA1 Mutation; BRCA2 Mutation; ATM Gene Mutation; PALB2 Gene Mutation,Niraparib; Irinotecan,,"University of California, San Francisco",GlaxoSmithKline,24,2023-05-23,2028-01-31,United States,No,https://clinicaltrials.gov/study/NCT05694715
NCT05743621,"A Phase I, Open-Label, Dose-Finding Study of TVB-2640 Administered in Combination With Enzalutamide (Xtandi) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)",Phase 1,Recruiting,Interventional,"Prostatic Neoplasms, Castration-Resistant",TVB-2640; Enzalutamide,,Weill Medical College of Cornell University,Sagimet Biosciences Inc.,30,2023-11-20,2029-01-25,United States,No,https://clinicaltrials.gov/study/NCT05743621
NCT05761782,Engaging Diverse and Underserved Communities in Cancer Awareness Training and Education (EDUCATE),,Recruiting,Observational,Cancer Awareness and Prevention Education,Education,,"University of California, Davis",,1500,2023-03-07,2025-03-07,United States,No,https://clinicaltrials.gov/study/NCT05761782
NCT05766371,A Phase 2 Study of Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Metastatic Castration Resistant Prostate Cancer,Phase 2,Recruiting,Interventional,Castrate Resistant Prostate Cancer; Metastatic Castration-resistant Prostate Cancer; Prostate Cancer; Prostate Carcinoma,Pembrolizumab; 177Lu-PSMA-617,,"University of California, San Francisco",Merck Sharp & Dohme LLC; Prostate Cancer Foundation,48,2023-12-15,2031-05-31,United States,No,https://clinicaltrials.gov/study/NCT05766371
NCT05806515,"S2210 A Phase II Study of Neoadjuvant Carboplatin for Localized, High Risk Prostate Cancer With Germline BRCA1/2 Mutations",Phase 2,Recruiting,Interventional,Prostate Adenocarcinoma; Stage IIIB Prostate Cancer AJCC v8; Stage IIIC Prostate Cancer AJCC v8,Biospecimen Collection; Carboplatin; Chest Radiography; Computed Tomography; Magnetic Resonance Imaging; PSMA PET Scan; Surgical Procedure,,SWOG Cancer Research Network,National Cancer Institute (NCI),44,2024-03-01,2031-06-05,United States,No,https://clinicaltrials.gov/study/NCT05806515
NCT05806814,Pilot Trial to Investigate Immune Response to an Extended Course of Sipuleucel-T Immunotherapy in Patients With Metastatic Castration-resistant Prostate Cancer (OU-SCC-EXCITE),Phase 1,Recruiting,Interventional,Metastatic Castration-Resistant Prostate Cancer (mCRPC),Sipuleucel-T,,University of Oklahoma,Dendreon,13,2023-11-12,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT05806814
NCT05820724,Prostate Specific Membrane Antigen (PSMA) Scan and Multiparametric MRI for Prostate Biopsy Detection of Clinically Significant Prostate Cancer,Phase 2,Not yet recruiting,Interventional,Prostate Cancer Diagnosis,PSMA PET scan; No PSMA PET; 18F- DCFPyl Injection,,VA Greater Los Angeles Healthcare System,Lantheus Medical Imaging,100,2023-05-01,2026-05-01,United States,No,https://clinicaltrials.gov/study/NCT05820724
NCT05849298,"An International Prospective Open-label, Multi-center, Randomized, Non-comparative Phase II Study of Lutetium [177Lu] Vipivotide Tetraxetan (AAA617) Alone and Lutetium [177Lu] Vipivotide Tetraxetan (AAA617) in Combination With Androgen Receptor Pathway Inhibitors in Patients With PSMA PET Scan Positive Castration-Resistant Prostate Cancer",Phase 2,Recruiting,Interventional,Prostatic Neoplasm,AAA617; AAA517; Piflufolastat F 18; ARPI; ADT; Best supportive care,,Novartis Pharmaceuticals,,80,2024-01-03,2030-05-18,Brazil; Canada; China; Czechia; France; Germany; Italy; Netherlands; Poland; Singapore; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT05849298
NCT05873192,Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in de Novo Metastatic to Lymph Nodes Prostate Cancer,Phase 2,Recruiting,Interventional,Prostate Cancer,ADT; Enzalutamide; Talazoparib; Degarelix; Luprolide,,M.D. Anderson Cancer Center,,30,2025-06-03,2028-12-31,United States,No,https://clinicaltrials.gov/study/NCT05873192
NCT05919329,Modulation of PSMA Expression in Castration Sensitive and Castration Resistant Prostate Cancer in Response to Hormonal Therapy,Phase 4,Recruiting,Interventional,Castration Resistant Prostate Cancer; Castration Sensitive Prostate Cancer; Prostate Adenocarcinoma,Piflufolastat; PSMA PET/CT Scan; PSMA PET/MRI scan; Biospecimen Collection; Electronic Health Record Review,,OHSU Knight Cancer Institute,"Oregon Health and Science University; Progenics Pharmaceuticals, Inc.",80,2024-06-25,2030-09-01,United States,No,https://clinicaltrials.gov/study/NCT05919329
NCT05929768,"Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study",Phase 3,Recruiting,Interventional,Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Early Stage Triple-Negative Breast Carcinoma,Biospecimen Collection; Carboplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Paclitaxel; Pembrolizumab; Quality-of-Life Assessment; Questionnaire Administration; Surgical Procedure,,SWOG Cancer Research Network,National Cancer Institute (NCI),2400,2023-09-15,2033-04-05,Mexico; Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT05929768
NCT05938270,"An Open-label, Randomised, Phase-I, Multi-Centre Study to Investigate the Biological Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men With Newly Diagnosed Prostate Cancer (ASCERTAIN)",Phase 1,Recruiting,Interventional,Prostate Cancer,Saruparib (AZD5305); Darolutamide; No Treatment,,AstraZeneca,,120,2023-09-21,2026-08-17,Australia; Canada; Netherlands; Spain; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05938270
NCT06004661,"An Open-label Dosimetry, Biodistribution, Tolerability and Safety Study of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Moderately and Severely Impaired and With Normal Renal Function.",Phase 2,Recruiting,Interventional,Metastatic Castration-Resistant Prostate Cancer (mCRPC),AAA617; 68Ga-PSMA-11,,Novartis Pharmaceuticals,,20,2024-04-04,2026-06-17,France; Germany; Italy; Spain; United States,No,https://clinicaltrials.gov/study/NCT06004661
NCT06062745,A Pilot Study for Detection of PSMA-Low Castration Resistant and Neuroendocrine Prostate Cancer With 18F-fluciclovine PET/CT Imaging,Phase 1,Recruiting,Interventional,Advanced Prostate Cancer; Metastatic Prostate Cancer; Metastatic Prostate Neuroendocrine Carcinoma,18F-fluciclovine; PET/CT,,Brigham and Women's Hospital,Blue Earth Diagnostics,30,2024-02-01,2028-09-01,United States,No,https://clinicaltrials.gov/study/NCT06062745
NCT06100705,"A Single Arm Open-label, Phase II Study of Sipuleucel-T With Bipolar Androgen Therapy in Men With Metastatic Castration-resistant Prostate Cancer",Phase 2,Recruiting,Interventional,Metastatic Castration-resistant Prostate Cancer,Testosterone Cypionate; Sipuleucel-T,,Yale University,Dendreon,26,2023-12-20,2028-03-05,United States,No,https://clinicaltrials.gov/study/NCT06100705
NCT06136650,"MK-5684-004: A Phase 3, Randomized, Open-label Study of Opevesostat Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA) (OMAHA-004)",Phase 3,Recruiting,Interventional,Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostatic Neoplasms,Opevesostat; Dexamethasone; Fludrocortisone acetate; Hydrocortisone; Abiraterone acetate; Prednisone acetate; Enzalutamide,,Merck Sharp & Dohme LLC,"Orion Corporation, Orion Pharma",1314,2023-12-18,2030-12-02,Australia; Brazil; Canada; Chile; China; Colombia; Costa Rica; Czechia; Estonia; France; Germany; Greece; Guatemala; Hong Kong; Hungary; Ireland; Israel; Italy; Japan; Latvia; Lithuania; Malaysia; Mexico; New Zealand; Peru; Portugal; Puerto Rico; Romania; Singapore; Slovakia; South Africa; South Korea; Spain; Sweden; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06136650
NCT06138067,A Pilot Study of Low Versus High Intensity Patient Navigation Program to Improve the Enrollment on Clinical Trials Among Cancer Patients,Not Applicable,Recruiting,Interventional,Prostate Cancer; Kidney Cancer,High intensity approach; Low intensity approach,,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,WellSpan Health,90,2025-12-01,2026-06-05,United States,No,https://clinicaltrials.gov/study/NCT06138067
NCT06145633,Vorinostat to Augment Response to 177Lutetium-PSMA-617 in the Treatment of Patients With PSMA-Low Metastatic Castration-Resistant Prostate Cancer,Phase 2,Recruiting,Interventional,Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8,Biopsy Procedure; Biospecimen Collection; Bone Scan; Computed Tomography; Fludeoxyglucose F-18; Gallium Ga 68 Gozetotide; Lutetium Lu 177 Vipivotide Tetraxetan; Positron Emission Tomography; Single Photon Emission Computed Tomography; Vorinostat,,Fred Hutchinson Cancer Center,Novartis; Institute for Prostate Cancer Research (IPCR); National Cancer Institute (NCI),15,2024-09-18,2027-12-30,United States,No,https://clinicaltrials.gov/study/NCT06145633
NCT06151223,A Prospective Registry for Patients at High-Risk for Pancreatic Cancer,,Recruiting,Observational,Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma,Bio-specimen Collection: Blood; Bio-specimen Collection: Pancreatic Juice; MRI,,Mayo Clinic,,5000,2021-07-13,2031-07-31,United States,No,https://clinicaltrials.gov/study/NCT06151223
NCT06177171,A Phase I/Ib Study of Olaparib and ASTX727 in BRCA1/2- and HRD-mutated Tumors,Phase 1,Recruiting,Interventional,BRCA1 Mutation; BRCA2 Mutation; BRCA Mutation; PALB2 Gene Mutation; Checkpoint Kinase 2 Gene Mutation; ATM Gene Mutation,Olaparib; ASTX727,,Pamela Munster,National Cancer Institute (NCI),18,2024-02-07,2027-02-28,United States,No,https://clinicaltrials.gov/study/NCT06177171
NCT06193486,A Phase I Clinical Trial of an Infusion of Autologous Gamma Delta T Cells Genetically Engineered With a Chimeric Receptor to Target the Prostate Stem Cell Antigen in Patients With Metastatic Castration Resistant Prostate Cancer,Phase 1,Recruiting,Interventional,Metastatic Castration-resistant Prostate Cancer,MSGV1-PSCA-8T28Z; Fludarabine; Cyclophosphamide,,H. Lee Moffitt Cancer Center and Research Institute,,30,2024-10-26,2033-12-13,United States,No,https://clinicaltrials.gov/study/NCT06193486
NCT06236139,Phase 1/2 Dose-Escalation and Cohort Study of STEAP1 CART With Enzalutamide in Participants With mCRPC,Phase 1/Phase 2,Recruiting,Interventional,Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8,Anti-STEAP1 CAR T-cells; Biopsy; Biospecimen Collection; Bone Scan; Computed Tomography; Cyclophosphamide; Echocardiography; Enzalutamide; Fludarabine; Leukapheresis; Magnetic Resonance Imaging; Multigated Acquisition Scan; Positron Emission Tomography,,Fred Hutchinson Cancer Center,"PromiCell Therapeutics, Inc.",48,2024-11-26,2027-03-30,United States,No,https://clinicaltrials.gov/study/NCT06236139
NCT06242470,"A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumor; Advanced Cancer; Metastatic Cancer; Squamous Cell Carcinoma of Head and Neck; Non Small Cell Lung Cancer; Small-cell Lung Cancer; Bladder Cancer; Sarcoma; Endometrial Cancer; Melanoma; Castration Resistant Prostatic Cancer; Cervical Cancer; Colorectal Cancer; Gastric Cancer; Gastro-esophageal Cancer; Pancreas Cancer; Clear Cell Renal Cell Carcinoma; Hepatocellular Carcinoma; Platinum-resistant Ovarian Cancer; Breast Cancer; Ovarian Cancer; Esophageal Squamous Cell Cancer (SCC),MGC026 Dose Escalation; MGC026 Dose for Expansion,,MacroGenics,,250,2024-03-06,2028-10-05,Australia; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06242470
NCT06257264,"A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Breast Cancer; Small Cell Lung Cancer; Ovarian Cancer; Gastric Cancer; Hormone-receptor-positive Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer; Advanced Solid Tumor; Endometrial Cancer; Prostate Cancer; TNBC - Triple-Negative Breast Cancer; GastroEsophageal Cancer; Bladder Cancer,BG-68501; Fulvestrant; BGB-43395,,BeiGene,,258,2024-03-11,2028-07-05,Australia; China; Israel; Moldova; New Zealand; United States,No,https://clinicaltrials.gov/study/NCT06257264
NCT06288113,Re-Treatment With 177Lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration Resistant Prostate Cancer: A Prospective Phase 2 Trial (RE-LuPSMA STUDY),Phase 2,Recruiting,Interventional,Castration-Resistant Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8,Biospecimen Collection; Computed Tomography; Gallium Ga 68 Gozetotide; Lutetium Lu 177 Vipivotide Tetraxetan; Positron Emission Tomography; Questionnaire Administration; Single Photon Emission Computed Tomography,,Jonsson Comprehensive Cancer Center,Novartis Pharmaceuticals,40,2024-08-01,2027-01-27,United States,No,https://clinicaltrials.gov/study/NCT06288113
NCT06305598,Bipolar Androgen Therapy in Metastatic Castration-Resistant Prostate Cancer (mCRPC),Phase 1,Recruiting,Interventional,Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8,Biopsy; Bone Scan; Computed Tomography; Leuprolide Acetate; Magnetic Resonance Imaging; Survey Administration; Testosterone Cypionate,,Roswell Park Cancer Institute,,14,2024-12-19,2027-12-15,United States,No,https://clinicaltrials.gov/study/NCT06305598
NCT06378866,MC230502 Dynamic Investigator Initiated Enterprise (DIVINE) in Prostate Cancer,Phase 2,Recruiting,Interventional,Recurrent Castration-Sensitive Prostate Carcinoma; Recurrent Prostate Cancer; Castration-resistant Prostate Cancer; Biochemically Recurrent Prostate Carcinoma,Abiraterone; Apalutamide; Biospecimen Collection; Bone Scan; Computed Tomography; Darolutamide; Degarelix; Enzalutamide; Goserelin; Histrelin; Leuprolide; Magnetic Resonance Imaging; Patient Observation; Positron Emission Tomography; Prednisone; Questionnaire Administration; Relugolix; Stereotactic Body Radiation Therapy; Triptorelin; Radiation Therapy; Image-Guided Therapy,,Mayo Clinic,National Cancer Institute (NCI),532,2024-06-03,2029-05-31,United States,No,https://clinicaltrials.gov/study/NCT06378866
NCT06398639,Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer,Not Applicable,Recruiting,Interventional,Prostate Cancer; Polygenic Risk Score,Polygenic Risk Score (PRS),,"Adam S. Kibel, MD",National Cancer Institute (NCI),1500,2024-05-07,2030-04-30,United States,No,https://clinicaltrials.gov/study/NCT06398639
NCT06457919,A Phase 1b/2 Study Evaluating the Activity of Tinengotinib (TT-00420) in Combination With Androgen Receptor Signaling Inhibitors (ARSIs) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC),Phase 1/Phase 2,Recruiting,Interventional,Prostate Cancer,Tinengotinib; abiraterone acetate with prednisone; Enzalutamide,,Memorial Sloan Kettering Cancer Center,TransThera Sciences,50,2024-06-04,2027-06-05,United States,No,https://clinicaltrials.gov/study/NCT06457919
NCT06470243,"A Phase III Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC), Stratified by Aggressive Variant Signature",Phase 3,Recruiting,Interventional,Castration-Resistant Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8,Biospecimen Collection; Bone Scan; Cabazitaxel; Carboplatin; Chest Radiography; Computed Tomography; Magnetic Resonance Imaging; Positron Emission Tomography; Prednisone,,SWOG Cancer Research Network,National Cancer Institute (NCI),528,2024-11-27,2032-04-05,United States,No,https://clinicaltrials.gov/study/NCT06470243
NCT06492122,"A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of [225Ac]Ac-FL-020 in Participants With mCRPC.",Phase 1,Recruiting,Interventional,Metastatic Castration-resistant Prostate Cancer,[225Ac]Ac-FL-020; Blood samples for PK; [111In]In-FL-020; Blood and urine samples collection; SPECT/CT images,,Full-Life Technologies GmbH,,35,2024-08-30,2026-12-05,Australia; Turkey (Türkiye); United States,No,https://clinicaltrials.gov/study/NCT06492122
NCT06520345,"A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177Lu) Rosopatamab Tetraxetan in Combination With Standard of Care Versus Standard of Care Alone in Patients With PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously After Androgen Receptor Pathway Inhibitor Treatment",Phase 3,Recruiting,Interventional,Metastatic Castration-resistant Prostate Cancer,177Lu-TLX591; Enzalutamide; Abiraterone; Docetaxel,,Telix Pharmaceuticals (Innovations) Pty Limited,,430,2024-07-26,2030-12-05,Australia; New Zealand; United States,No,https://clinicaltrials.gov/study/NCT06520345
NCT06533644,"A Phase 2a Multicenter, Dose-Escalation and Dose Optimization Study of SYNC-T Therapy SV-102 for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)",Phase 2,Recruiting,Interventional,Metastatic Castration-resistant Prostate Cancer,Partial Oncolysis; SV-102,,"Syncromune, Inc.",,70,2025-05-29,2027-12-14,United States,No,https://clinicaltrials.gov/study/NCT06533644
NCT06545955,"A Phase 3, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)",Phase 3,Recruiting,Interventional,Non-muscle Invasive Bladder Cancer With Carcinoma in Situ,Nadofaragene Firadenovec; Gemcitabine; Docetaxel; Pembrolizumab,,Ferring Pharmaceuticals,,250,2024-10-01,2030-12-31,Canada; Czechia; Poland; Spain; United States,No,https://clinicaltrials.gov/study/NCT06545955
NCT06551324,"A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)",Phase 3,Recruiting,Interventional,Metastatic Castrate Resistant Prostate Cancer (mCRPC),PF-06821497; Docetaxel; Enzalutamide,,Pfizer,,600,2024-10-21,2028-10-29,Argentina; Australia; Brazil; Canada; China; Czechia; France; Germany; Greece; Hungary; Italy; Japan; Netherlands; Poland; Slovakia; South Africa; South Korea; Spain; Sweden; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06551324
NCT06555588,Engage: A Randomized Controlled Trial Testing the Efficacy of a Telehealth-Delivered Psychosocial Intervention to Decrease Symptom Interference in Patients With Advanced Cancer,Not Applicable,Recruiting,Interventional,Advanced Breast Cancer; Advanced Prostate Cancer; Advanced Lung Cancer; Advanced Colorectal Carcinoma; Advanced Colorectal Adenocarcinoma,ENGAGE; Supportive Care,,Duke University,National Cancer Institute (NCI),190,2025-06-11,2028-11-05,United States,No,https://clinicaltrials.gov/study/NCT06555588
NCT06568562,PRO-XL: A Phase II Study of XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer After Progression on Lutetium-177 (177Lu)-PSMA-617,Phase 2,Recruiting,Interventional,Metastatic Castration-resistant Prostate Cancer,XL092,,University of Utah,Exelixis,32,2024-12-09,2028-12-05,United States,No,https://clinicaltrials.gov/study/NCT06568562
NCT06574880,STARLiT: STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer: A Phase I/II Trial,Phase 1/Phase 2,Recruiting,Interventional,Malignant Neoplasm of Prostate; Locally Advanced Prostate Cancer,Lu-PSMA-617; 5-fraction Stereotactic Body Radiation Therapy (SBRT),,"Angela Y. Jia, MD PhD",,45,2025-05-13,2027-03-01,United States,No,https://clinicaltrials.gov/study/NCT06574880
NCT06582017,A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma,Phase 1,Recruiting,Interventional,Ovarian Cancer; Pancreas Cancer; Urothelial Carcinoma; Renal Cell Carcinoma; Hepatocellular Carcinoma; Gastrointestinal Cancer; Lung Cancer; Prostate Cancer; Breast Cancer,QXL138AM Injection every 2 weeks by IV Infusion,,Nammi Therapeutics Inc,,100,2024-08-28,2028-05-30,United States,No,https://clinicaltrials.gov/study/NCT06582017
NCT06609005,"A Phase 1 and Phase 2, Multi-Center, Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Evidence of Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer",Phase 1/Phase 2,Recruiting,Interventional,Advanced Metastatic Castration Resistant Prostate Cancer,INV-9956,,"Shenzhen Ionova Life Sciences Co., Ltd.",,84,2025-01-23,2028-01-17,China; United States,No,https://clinicaltrials.gov/study/NCT06609005
NCT06629779,"A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2)",Phase 3,Recruiting,Interventional,Metastatic Castration-Resistant Prostate Cancer,PF-06821497; Placebo; Enzalutamide,,Pfizer,,900,2024-10-22,2028-11-30,Argentina; Brazil; Bulgaria; Canada; Chile; China; Czechia; Denmark; Finland; France; Germany; Greece; Hungary; Italy; Japan; Netherlands; New Zealand; Poland; Slovakia; South Africa; South Korea; Spain; Sweden; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06629779
NCT06632977,PREcision DIagnostics in Prostate Cancer Treatment (PREDICT),Phase 2,Recruiting,Interventional,Castration-Resistant Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8,Genetic testing; Valemetostat Tosylate; Magnetic Resonance Imaging; Computed Tomography; Bone scan; FDG-Positron Emission Tomography; PSMA PET Scan; Biospecimen Collection; Carboplatin; Cabazitaxel; Abiraterone Acetate; Enzalutamide; Lutetium Lu 177 Vipivotide Tetraxetan,,Alliance for Clinical Trials in Oncology,National Cancer Institute (NCI),474,2025-02-06,2034-10-11,United States,No,https://clinicaltrials.gov/study/NCT06632977
NCT06659614,Prostate Tissue Biobank for People at Genetic Risk for Aggressive Disease,,Recruiting,Observational,Prostate Cancer; Genetic Predisposition,,,Abramson Cancer Center at Penn Medicine,,200,2024-01-01,2034-01-05,United States,No,https://clinicaltrials.gov/study/NCT06659614
NCT06674863,Addressing Health Literacy With a Tailored Survivorship Care Plan to Improve Access in Underserved African American Prostate Cancer Patients,Not Applicable,Recruiting,Interventional,Localized Prostate Carcinoma; Oligometastatic Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8,Educational Intervention; Interview; Questionnaire Administration; Supportive Care; Supportive Care,,Emory University,National Cancer Institute (NCI); United States Department of Defense,150,2025-11-07,2030-12-31,United States,No,https://clinicaltrials.gov/study/NCT06674863
NCT06691984,"A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy",Phase 3,Recruiting,Interventional,Metastatic Castration-resistant Prostate Cancer,Xaluritamig; Abiraterone; Enzalutamide; Cabazitaxel,,Amgen,,675,2024-12-09,2029-07-30,Australia; Austria; Belgium; Canada; Denmark; France; Germany; Greece; Hong Kong; Italy; Japan; Netherlands; Poland; Singapore; South Korea; Spain; Sweden; Switzerland; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06691984
NCT06710379,A Phase 1a/b Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors,Phase 1,Recruiting,Interventional,Solid Tumors,ADRX-0405,,Adcentrx Therapeutics,,68,2024-12-30,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT06710379
NCT06764485,"A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge",Phase 3,Recruiting,Interventional,Metastatic Castration-resistant Prostate Cancer,BMS-986365; Enzalutamide; Abiraterone; Docetaxel; Predinsone/Prednisolone,,Celgene,,960,2025-03-13,2029-01-19,Argentina; Australia; Austria; Brazil; Canada; Chile; China; Czechia; Denmark; France; Germany; India; Ireland; Italy; Japan; Poland; Puerto Rico; Romania; Slovakia; South Korea; Spain; Sweden; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06764485
NCT06785636,"A Phase 1b/2a, MultiCenter, Open- Label Study of Pocenbrodib as Monotherapy or in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)",Phase 1/Phase 2,Recruiting,Interventional,"mCRPC (Metastatic Castration-resistant Prostate Cancer); Genital Neoplasms, Male; Urogenital Neoplasms; Urogenital Cancers; Prostatic Diseases; Prostatic Neoplasms; Male Urogenital Diseases; Neoplasms; Neoplasms by Site; Prostate Cancer","Pocenbrodib; Cohort 2A (Pocenbrodib monotherapy), Cohort 2B (Pocenbrodib + abiraterone acetate), Cohort 2C (Pocenbrodib + olaparib), Cohort 2D (Pocenbrodib + 177Lu-PSMA-617",,"Pathos AI, Inc.",Duke University,252,2025-02-07,2029-04-30,United States,No,https://clinicaltrials.gov/study/NCT06785636
NCT06800313,Phase 1/2 Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC),Phase 1/Phase 2,Recruiting,Interventional,Prostate Cancer Metastatic Disease; Prostate Cancer (Adenocarcinoma),HLD-0915,,"Halda Therapeutics OpCo, Inc.",,33,2025-02-24,2027-03-05,United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06800313
NCT06801236,"A Phase 1 Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ACE-232 in Patients With Metastatic Castration-Resistant Prostate Cancer (CRPC)",Phase 1,Recruiting,Interventional,Prostate Cancer (Adenocarcinoma); mCRPC (Metastatic Castration-resistant Prostate Cancer),ACE-232 tablets,,Acerand Therapeutics (Hong Kong) Limited,,67,2025-05-12,2028-08-01,United States,No,https://clinicaltrials.gov/study/NCT06801236
NCT06824818,A Feasibility Trial of LHRH Agonist Discontinuation in Elderly Prostate Cancer Patients,Not Applicable,Recruiting,Interventional,Elderly; Prostate Cancer,LHRH Agonist Therapy Discontinuation,,University of Chicago,,155,2026-06-05,2027-06-05,United States,No,https://clinicaltrials.gov/study/NCT06824818
NCT06826768,A Phase Ib Clinical Trial to Optimize Risk Benefit of REGN5678 (PSMAxCD28 Bispecific Antibody) Plus Cemiplimab (Anti-PD-1 Monoclonal Antibody) in Patients With Metastatic Castration-resistant Prostate Cancer,Phase 1,Recruiting,Interventional,Prostate Cancer,REGN5678; Cemiplimab,,M.D. Anderson Cancer Center,Regeneron Pharmaceuticals,60,2025-07-09,2029-05-01,United States,No,https://clinicaltrials.gov/study/NCT06826768
NCT06906471,"A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS",Phase 1/Phase 2,Not yet recruiting,Interventional,Prostate Cancer; Prostate Cancer (Adenocarcinoma); Fluorescence Imaging,AS1986NS,,"Antelope Surgical Solutions, Inc",,10,2025-12-05,2026-03-05,Taiwan; United States,No,https://clinicaltrials.gov/study/NCT06906471
NCT06907043,"A Phase 1/2, Open-label, Multicenter, Dose-escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants With Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumors,EIK1004-001 (IMP1707-001),,Eikon Therapeutics,"Impact Therapeutics, Inc.",130,2025-04-30,2028-12-05,Australia; China; United States,No,https://clinicaltrials.gov/study/NCT06907043
